Scarica l'app Stockscreener
72.38
1.59%
1.13
Pre-mercato:
72.52
0.14
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$71.25
Aprire:
$71.3
Volume 24 ore:
4.60M
Relative Volume:
0.83
Capitalizzazione di mercato:
$27.93B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
30.96
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+3.43%
1M Prestazione:
-0.66%
6M Prestazione:
+3.56%
1 anno Prestazione:
-12.72%
Intervallo 1D:
$69.74
$72.77
Intervallo di 1 settimana:
$67.30
$72.77
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.38 | 25.99B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
DXCMDexcom Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Did FDA-Backed Stelo Expansion Beyond Insulin Users Just Shift DexCom's (DXCM) Investment Narrative? - Sahm
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – SIX:DXCM - TradingView
Devon Energy expands Permian drilling plan, shares tied to oil price swings - AD HOC NEWS
Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)Recover - The National Law Review
DexCom, Inc. (DXCM) Investor Outlook: Seizing a 21.53% Upside in the Booming CGM Market - DirectorsTalk Interviews
Dexcom Inc. extends Stelo reach, shares in focus on NASDAQ - AD HOC NEWS
DexCom Continues Push Towards Universal Glucose Biosensing with Latest AdvancesEarnings Risk Report - dars.gov.et
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All - Insider Monkey
Did You Lose Money on DexCom, Inc. (DXCM)? Levi & Korsinsky Urges Investors to Act Before December 26, 2025 - The National Law Review
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - The National Law Review
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. InvestorsLead Plaintiff Deadline December 26, 2025 - The National Law Review
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - The National Law Review
Deutsche Bank Names Top Healthcare Stocks Led by DexCom and Insulet - Investing.com Canada
Dexcom G7 from Dexcom Inc.smaller sensor, quicker warm-up and app-first thinking - Ad-hoc-news.de
The STACK oil gathering system from Devon Energy Corp.quietly critical for getting barrels to mar - Ad-hoc-news.de
DexCom (DXCM) Stock After Three-Year 45% Slide Is The Market Too Pessimistic - Yahoo Finance
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Dexcom Inc launches redesigned Stelo app, shares trade around key Nasdaq level - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (NASDAQ:DXCM) - TradingView
Devon Energy consensus steady, shares track U.S. oil peers - Ad-hoc-news.de
DexCom, Inc. Actuals & Estimates (HAN:DC4) - TradingView
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Dexcom reports clear analyst support, shares trade below new Deutsche Bank target - Ad-hoc-news.de
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
DexCom (DXCM) Launches New Stelo App As It Expands Into Four Countries - Sahm
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DexCom, Inc. Actuals & Estimates (FWB:DC4) - TradingView
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
DexCom Inc. (NASDAQ:DXCM): Why Healthcare Is Watching? - Kalkine Media
DexCom, Inc. Actuals & Estimates (SIX:DXCM.USD) - TradingView
DXCM Forecast — Price Target — Prediction for 2027 - TradingView
Dexcom alerts users after stolen G7 sensors allegedly sold by unauthorized distributor - Class Action Lawsuits
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans - The Globe and Mail
Dexcom - Forbes
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jun 15 '26 |
Sale |
74.13 |
4,000 |
296,540 |
52,852 |
1.51%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):